ArticleJournal of gynecologic oncology2026
Adjuvant concurrent chemoradiotherapy for early-stage cervical cancer patients with intermediate-risk factors in the era of intensity-modulated radiation therapy.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether adjuvant concurrent chemotherapy with pelvic intensity-modulated radiotherapy (IMRT) improves the outcome of patients with early-stage cervical cancer with intermediate risk factors (IRFs) compared with IMRT alone.
methodsThis study included a cohort of 244 women from January 2012 to October 2023 who underwent radical hysterectomy along with pelvic lymph node dissection (PLND) for stage IB-IIA cervical cancer with IRFs. One hundred thirty-nine patients were postoperatively treated with pelvic IMRT (45.0-50.4 Gy) and adjuvant concurrent chemoradiotherapy (CCRT) (weekly cisplatin or weekly or triweekly combination of paclitaxel and cisplatin). One hundred five patients were treated with pelvic IMRT alone. The significance of clinical parameters, overall survival (OS), and recurrence-free survival (RFS) of each arm were analyzed.
resultsThe median follow-up period was 61.2 months, with a range spanning from 6.3 to 144.4 months. The 5-year OS rates in the patients in the radiotherapy (RT) and CCRT arms were 96.7% and 94.4%, respectively (p=0.271). Five-year RFS was 88.1% in the RT arm and 86.9% in the CCRT arm (p=0.740). Multivariate analysis identified adenocarcinoma (AC) histology as the only significant prognostic factor affecting OS and RFS.
conclusionThis study demonstrates that even in the era of IMRT, CCRT is not more effective than RT alone in patients with stage IB-IIA cervical cancer with IRFs following radical hysterectomy with PLND.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.